PANews reported on June 19 that according to The Block, the stablecoin issuer Paxos launched a new startup Paxos Labs, which aims to help institutions integrate DeFi and on-chain productsPANews reported on June 19 that according to The Block, the stablecoin issuer Paxos launched a new startup Paxos Labs, which aims to help institutions integrate DeFi and on-chain products

Paxos launches new startup to help institutions offer DeFi products

2025/06/19 00:04

PANews reported on June 19 that according to The Block, the stablecoin issuer Paxos launched a new startup Paxos Labs, which aims to help institutions integrate DeFi and on-chain products directly into their own applications and platforms. Paxos Labs co-founder Bhau Kotecha said that due to the company's growing demand for connecting DeFi markets and real-world asset opportunities, the company has been incubated within Paxos in the past six months. Paxos Labs is building an easy-to-integrate API that allows customers to integrate related products without having to deeply understand the complexity of DeFi. Its initial products include tools for issuing customized branded stablecoins, deploying tokenized income strategies, and managing structured digital assets. Its main target customers are consumer financial technology applications, exchanges, and blockchain networks.

Paxos Labs will also work with multi-asset issuers to support customized stablecoins, while leveraging Paxos's experience in regulation, infrastructure, and financial system building. Unlike companies that focus on custody or direct access to DeFi protocols, Paxos Labs focuses on providing APIs and infrastructure for platforms to provide on-chain products to end users. In the next 12 to 18 months, its goal is to become a one-stop shop for institutional integrated on-chain products.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…
Share
BitcoinEthereumNews2025/09/26 19:16
Share